Core Insights - Windtree Therapeutics has entered a global license agreement for acute pulmonary treatments that could yield up to $78.9 million in milestone payments and low double-digit royalties [1][3] - The licensed treatments include SURFAXIN, lyophilized lucinactant, and AEROSURF, aimed at treating respiratory distress syndrome (RDS) in premature infants [1][4] - The licensing partner is responsible for all development and commercialization costs, allowing Windtree to focus on its corporate strategy without dilution [3] Company Overview - Windtree Therapeutics is a diversified company with multiple divisions, focused on becoming a revenue-generating entity with future profitability [3] - The company is actively involved in the development of innovative treatments for RDS, a serious condition affecting premature infants [3][2] Treatment Details - Lyophilized lucinactant is an investigational synthetic peptide designed to manage RDS in premature infants who may lack fully developed natural lung surfactant [4] - AEROSURF is a drug/device combination that delivers aerosolized KL4 surfactant noninvasively, potentially reducing the need for invasive procedures [4] - SURFAXIN, a synthetic drug previously approved by the FDA, was designed to prevent RDS but is no longer available in the U.S. [5]